Abstract

Objective
To evaluate whether nephrotoxicity differs between nafcillin and piperacillin-tazobactam in adult hospitalized patients.
Introduction
Acute kidney injury (AKI) is a significant cause of morbidity and mortality in the inpatient setting, with antibiotics being a significant contributor. There is evidence of an increased risk of nephrotoxicity with the combination of vancomycin and piperacillin-tazobactam compared to vancomycin and cefepime or vancomycin alone. It is unknown whether this effect is exclusive for piperacillin-tazobactam. Therefore, in order to promote optimal medication therapy for inpatient bacterial infections, there is a need to assess the persistence of this difference in other beta-lactam antibiotics.
Methods
A single-center, retrospective cohort study was performed utilizing electronic health records at University of Kentucky Healthcare. Adult hospitalized patients being treated with nafcillin or piperacillin-tazobactam from September 1, 2010 to September 1, 2014 were included in the study. Age, sex, Charlson Comorbidity Index, baseline creatinine clearance, dehydration, hypotension, exposure to concomitant nephrotoxins, and duration of therapy were evaluated. The primary outcome was AKI as defined by the RIFLE criteria (risk, injury, failure, loss of kidney function, and end-stage kidney disease), where risk, injury, and failure were defined as a 25%,
Introduction
The incidence of acute kidney injury (AKI) is estimated to be between 5.7% and 18.0%.
Development of AKI can lead to significant increases in length of stay, healthcare costs, and mortality, with in-hospital mortality ranging from 50.5% to 76.8%. [1] [2] [3] AKI can occur as a result of a number of factors including cardiac insufficiency, sepsis, malignancy, liver insufficiency, and autoimmune diseases. 3 Drug-induced nephrotoxicity is also a significant cause of AKI and has been shown to be associated with angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), acyclovir, aminoglycosides, amphotericin B, beta-lactam antibiotics, IV contrast, and non-steroidal anti-inflammatory drugs (NSAIDs), among others. 4, 5 Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor combination broad-spectrum antibiotic commonly used to empirically treat for many gram-positive and gram-negative infections. Incidence of nephrotoxicity in piperacillin-tazobactam has been reported to be 9.0% to 18.2%. [6] [7] [8] There is little data demonstrating the mechanism of nephrotoxicity of piperacillintazobactam, although in few studies indicate acute interstitial nephritis (AIN) is the most likely cause. [9] [10] [11] [12] 37 Piperacillin-tazobactam has also been shown to cause a lower rate of renal recovery compared to other antibiotics. 13 The combination of vancomycin, a glycopeptide antibiotic used to treat gram-positive infections, with piperacillin-tazobactam has a higher incidence of nephrotoxicity than vancomycin alone. 14, 15 In yet to be published data from a study conducted at the University of Kentucky, the combination of vancomycin and piperacillin-tazobactam also had a higher incidence of nephrotoxicity than combination of vancomycin and cefepime, another broad-spectrum betalactam antibiotic. It is unknown whether this effect is exclusive for piperacillin-tazobactam or if it also exists in other beta-lactam antibiotics.
Nafcillin is a narrow-spectrum beta-lactam antibiotic used most commonly as one of the first line treatments for methicillin-sensitive Staphylococcus aureus (MSSA) infections. Incidence of nephrotoxicity of nafcillin has been shown to be 11.4%. 16 Nafcillin has been reported as the most probable cause of acute interstitial nephritis (AIN) in a number of cases. [17] [18] [19] The purpose of this study is to investigate the difference in nephrotoxicity between nafcillin and piperacillin-tazobactam in adult hospitalized patients. The results of this study may aid in the selection of medication therapy for inpatient bacterial infections.
Methods
Study sample
A single-center, retrospective cohort study was conducted at University of Kentucky Healthcare, a tertiary care academic medical center. All patients admitted between September 1, 2010 and September 1, 2014 without renal dysfunction at initiation, chronic kidney disease, structural kidney disease, or pre-existing dialysis were eligible for the study. Patients with kidney disease at baseline were excluded to allow for assessment of the effects of the study antibiotics. Each admission was treated as an independent event. Patients receiving either nafcillin or piperacillintazobactam were included. Patients were excluded from the piperacillin-tazobactam group if they received therapy with vancomycin in order to isolate the effects of the study drug. Those in the nafcillin group may have received up to 5 days of vancomycin or piperacillin-tazobactam to remain in the study due to clinical use of nafcillin typically being after initial treatment with more broad-spectrum empiric therapy. Other exclusion criteria include length of stay less than 2 days, age less than 18 years, baseline creatinine clearance greater than 4 times the standard deviation of the mean or less than 30 mL/min, days of antibiotic therapy less than 2 days, and AKI prior to treatment index, within 48 hours of treatment index, or greater than 7 days after treatment was discontinued. Minimum limits were used for length of stay and duration of antibiotic therapy to exclude AKI events due to previous exposures. These criteria were applied for timeframe of AKI to limit events to those that occurred due to the study drugs. Patients who did not have serum creatinine values were also excluded from analysis. This study was exempt from IRB approval as only de-identified data were used. Charlson Comorbidity Index is a measure of illness severity based on a patient's medical history.
Data collection and measures
Baseline creatinine clearance was based on the first measured serum creatinine. Hypotension was determined by the composite of hypotension diagnosis, mean arterial pressure less than 60 mmHg, and/or use of vasopressor or inotrope therapy. Concomitant nephrotoxins assessed include acyclovir, aminoglycosides, amphotericin B, ACEIs, ARBs, colistin, cyclosporine, foscarnet, IV contrast, loop diuretics, NSAIDS, sulfonamides, tacrolimus, and tenofovir. Patients received one point for each of the nephrotoxins studied to give a total number of concomitant nephrotoxins received. Duration of therapy was defined as the number of unique days patient received at least one dose of study antibiotic.
Study outcomes
The primary outcome was the difference in AKI between nafcillin and piperacillin-tazobactam as defined by the RIFLE criteria based on percent change from baseline creatinine clearance to minimum creatinine clearance. This was evaluated both in patients being treated with nafcillin with exposure to piperacillin-tazobactam and/or vancomycin for 5 days or less, as well as the nafcillin only group. The RIFLE criteria is the first consensus definition of AKI. 20 Within the RIFLE criteria there are 3 severity classes, risk, injury, and failure, which are a 25%, 50%, and 75% decrease in glomerular filtration rate (GFR) from baseline. GFR is a measure of kidney function and is based on the adjusted Cockcroft-Gault equation. In addition, there are two outcome classes, loss of kidney function and end-stage kidney disease. The current study did not evaluate outcome classes because diagnosis based on duration of renal dysfunction is required, a variable that was not collected. The RIFLE criteria has been largely validated to identify AKI, classify severity, and correlate with patient outcome.
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Secondary outcomes include time to AKI from initiation of antibiotic therapy, hospital length of stay, and mortality, where mortality is a composite of inpatient mortality and transfer to hospice service.
Statistical analysis
Basic descriptive statistics were used to assess the characteristics of the study population. 
Results
A total of 31,854 patients were screened for study participation (Figure 1 ). Based on antibiotic exposure, length of stay less than 2 days, age less than 18 years, lack of serum creatinine values, baseline creatinine clearance greater than 4 times the standard deviation of the mean (~406 mL/min) or less than 30 mL/min, days of therapy less than 2 days, and AKI prior to treatment index, within 48 hours of treatment index, or greater than 7 days after treatment was discontinued, 28,461 patients were excluded. The final sample consisted of 272 patients in the nafcillin study group and 3,121 patients in the piperacillin-tazobactam study group.
Patient population
The mean age of patients in the nafcillin group was 47. (Table 4) .
Secondary outcomes
The mean time to AKI was 6.00 ± 5.14 days in the nafcillin group and 4.69 ± 3.41 days in the piperacillin-tazobactam group (p=0.0458). The mean hospital length of stay was 14.38 ± 12.69 days in the nafcillin group and 7.44 ± 7.55 days in the piperacillin-tazobactam group (p<0.0001).
Mortality occurred in 135 (3.98%) patients in the total study population, with 23 (8.46%) in the nafcillin group and 112 (3.59%) in the piperacillin-tazobactam group (p<0.0001) ( Table 5) .
Discussion
This study aimed to evaluate whether nephrotoxicity differs between nafcillin and piperacillin- Results from this study agree with current literature, although the incidence of AKI in nafcillin was higher compared to previous studies. In a yet to be published study from the University of Kentucky, vancomycin in combination with piperacillin-tazobactam had a significantly higher incidence of nephrotoxicity than vancomycin in combination with cefepime, with rates of 30% and 18%, respectively (p<0.0001). 14 The incidence of AKI was also shown to be different depending on the dosing scheme of piperacillin-tazobactam, with a higher rate in those who received 4.5 grams every 6 hours compared to those who received 3.375 grams every 6 hours. In a study evaluating a population of diabetic patients with osteomyelitis, acute renal failure was seen in 29.3% of patients being treated with combination of vancomycin with piperacillintazobactam compared to 13.3% in patients treated with vancomycin in combination with cefepime. 29 In a third study, incidence of AKI was 34.8% in the vancomycin and piperacillin-tazobactam combination group compared to 12.5% in the vancomycin and cefepime group. 30 There is also evidence of an increase in incidence of nephrotoxicity of vancomycin in combination with piperacillin-tazobactam compared to vancomycin alone. 6, 15, 25, 26 There are a number of limitations associated with this study. This was a single center study conducted at University of Kentucky Healthcare and, therefore, results may not be generalizable to other hospitals serving different populations with differing levels of acuity. In addition, due to the retrospective nature of this study, there are many variables with potential to affect results that were unable to be collected, leading to residual confounding. One of these includes indication for antibiotics or microbiology results. Piperacillin-tazobactam is a broad-spectrum antibiotic that is often used for empiric therapy when an infection is suspected, however culture and susceptibilities or source of infection are unknown. Once more information is known about an infection, therapy is often switched to a more narrow-spectrum antibiotic such as nafcillin for an MSSA infection. This is likely the reason the number of patients in each group is different with the sample size in nafcillin being significantly smaller. This may also lead to nafcillin being used for longer durations compared to piperacillin-tazobactam, which may only be used for a short period of time before switching to an antibiotic targeting a specific bacterium.
Another limitation is temporality. This study assessed exposure to concomitant nephrotoxins, hypotension, and dehydration at any point during a patient's hospital stay rather than in relation to development of AKI. The amount and duration of exposure was not analyzed, and exposure to different nephrotoxins was treated the same and combined into a number of concomitant nephrotoxins group, although different medications may have differing levels of nephrotoxicity.
This study excluded patients in the piperacillin-tazobactam group who received vancomycin, however included patients in the nafcillin group if they received up to 5 days of therapy with vancomycin or piperacillin-tazobactam. This was due to the clinical use of nafcillin typically being after initial treatment with a more broad-spectrum antibiotic such as piperacillintazobactam and/or vancomycin. The differing levels of exposure to vancomycin is another limitation of this study and may have an effect on the odds of nephrotoxicity in nafcillin.
Exposure to vancomycin was excluded in the piperacillin-tazobactam group to try to isolate the effect of the study drug. However, nephrotoxicity due to vancomycin is not expected to develop within that timeframe; it has been shown that nephrotoxicity occurs after 7 days of therapy.
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Interestingly, time to AKI was longer in nafcillin, which is not what would be expected if exposure to vancomycin was contributing to this effect.
Additionally, for patients transferred in from an outside hospital, information about their previous hospital stay prior to coming to University of Kentucky Healthcare was not available to be evaluated.
Another possible limitation is use of the RIFLE criteria as a measure of nephrotoxicity. Prior to the introduction of the RIFLE criteria in 2004, a number of definitions of AKI were used. The RIFLE criteria has been largely validated to identify AKI, classify severity, and correlate with patient outcome. [21] [22] [23] [24] There has been an almost linear relationship seen between risk classification in the RIFLE criteria and hospital mortality. 23 The RIFLE criteria is limited by its requirement of baseline renal function, or an estimate from the Modification of Diet in Renal Disease (MDRD) equation. It has been modified in an attempt to increase sensitivity and specificity with the Acute Kidney Injury Network (AKIN) criteria, which was introduced in 2007. With the AKIN criteria, baseline serum creatinine is not required. However, AKIN criteria could not be used in this study because it requires adequate hydration status in order to diagnose AKI, which could not be ensured due to the retrospective nature of this study. 28 Although these limitations exist, it has been shown that these two classification schemes are largely similar in identifying AKI and have no difference in ability to predict mortality. [29] [30] [31] Creatinine clearance is used to estimate GFR, however it itself has limitations in its ability to measure kidney function. Biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) are currently being investigated as new ways to classify AKI earlier.
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Conclusion
The odds of AKI overall and risk classification were higher in the nafcillin group compared to the piperacillin-tazobactam group, although this difference did not persist in the injury and failure categories. The mean time to AKI and hospital length of stay were longer in nafcillin patients, and the incidence of mortality was also higher in the nafcillin group. This study suggests that beta-lactam antibiotics overall may contribute to nephrotoxicity in adult hospitalized patients, with nafcillin carrying a significantly greater potential for AKI than piperacillin-tazobactam. However, further analysis should be done to assess the impact of risk factors in contributing to this rate of nephrotoxicity since patients in the nafcillin group had greater exposure to concomitant nephrotoxins and a longer duration of therapy. This study was exempt from IRB approval as only de-identified data were used.
